1.2950
-0.0600
(-4.43%)
At close: 4:10:22 PM GMT+10
Breakdown
TTM
6/30/2024
6/30/2023
6/30/2022
6/30/2021
Total Revenue
5,315.3750
5,315.3750
4,243.0690
1,531.7180
1,017.9620
Cost of Revenue
1,626.9530
1,626.9530
1,026.1550
702.6100
625.6450
Gross Profit
3,688.4220
3,688.4220
3,216.9140
829.1080
392.3170
Operating Expense
15,886.6180
15,886.6180
14,111.5870
12,702.3340
12,497.2640
Operating Income
-12,198.1960
-12,198.1960
-10,894.6730
-11,873.2260
-12,104.9470
Net Non Operating Interest Income Expense
971.1560
971.1560
850.7930
84.1290
199.2420
Other Income Expense
416.9960
416.9960
79.1980
189.9380
38.6310
Pretax Income
-10,232.4420
-10,232.4420
-9,410.5610
-11,250.5400
-11,431.4220
Tax Provision
-3,051.4830
-3,051.4830
-3,162.3800
-2,143.9550
-2,394.3970
Net Income Common Stockholders
-7,180.9590
-7,180.9590
-6,248.1810
-9,106.5850
-9,037.0250
Basic EPS
-0.04
--
-0.03
-0.05
-0.05
Diluted EPS
-0.04
--
-0.03
-0.05
-0.05
Basic Average Shares
202,008.3400
--
197,213.3930
194,665.8340
186,852.6700
Diluted Average Shares
202,008.3400
--
197,213.3930
194,665.8340
186,852.6700
Net Income from Continuing & Discontinued Operation
-7,180.9590
-7,180.9590
-6,248.1810
-9,106.5850
-9,037.0250
Normalized Income
-7,180.9590
-7,180.9590
-6,248.1810
-9,106.5850
-9,037.0250
Interest Income
1,031.6810
1,031.6810
850.7930
84.1290
199.2420
Net Interest Income
971.1560
971.1560
850.7930
84.1290
199.2420
EBIT
-12,198.1960
-12,198.1960
-10,894.6730
-11,873.2260
-12,104.9470
EBITDA
-11,681.1190
-11,681.1190
-10,340.5520
-11,524.6070
-11,669.2950
Reconciled Cost of Revenue
1,626.9530
1,626.9530
1,026.1550
702.6100
625.6450
Reconciled Depreciation
517.0770
517.0770
554.1210
348.6190
435.6520
Net Income from Continuing Operation Net Minority Interest
-7,180.9590
-7,180.9590
-6,248.1810
-9,106.5850
-9,037.0250
Normalized EBITDA
-11,681.1190
-11,681.1190
-10,340.5520
-11,524.6070
-11,669.2950
Tax Rate for Calcs
0.0003
0.0003
0.0003
0.0002
0.0002
6/30/2021 - 8/12/2014
Upgrade to begin using 40 years of financial statements and get so much more.
Perform in-depth fundamental analysis with decades of income statements, balance sheets, and cash flows — all exportable.
UpgradeRelated Tickers
OPT.AX Opthea Limited
0.6000
0.00%
PAR.AX Paradigm Biopharmaceuticals Limited
0.2900
-7.94%
DXB.AX Dimerix Limited
0.4250
+1.19%
BOT.AX Botanix Pharmaceuticals Limited
0.3950
+2.60%
NUZ.AX Neurizon Therapeutics Limited
0.1200
+20.00%
CYP.AX Cynata Therapeutics Limited
0.1950
0.00%
AGN.AX Argenica Therapeutics Limited
0.6800
0.00%
RAC.AX Race Oncology Limited
0.9250
-2.63%
LTP.AX LTR PHARMA FPO [LTP]
0.3850
+2.67%
TLX.AX Telix Pharmaceuticals Limited
25.69
-0.70%